Kashmik Formulation plans 50 per cent production capacity expansion and targets ₹100 crore revenue in FY26
Express Pharma
JUNE 26, 2025
To support this, the company is investing approximately ₹20 crore in infrastructure development, which is already underway. The company generates around 70 per cent of its revenue from its own branded generics and 20–30 per cent from contract manufacturing for established pharmaceutical companies.
Let's personalize your content